Nizar N. Zein, MD, FAASLD

Mansour A. Parsi, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Ashish Atreja, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Nizar N. Zein, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Address: Mansour A. Parsi, MD, Department of Gastroenterology and Hepatology, A31, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail parsim@ccf.org

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Mansour A. Parsi, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Ashish Atreja, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Nizar N. Zein, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Address: Mansour A. Parsi, MD, Department of Gastroenterology and Hepatology, A31, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail parsim@ccf.org

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Mansour A. Parsi, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Ashish Atreja, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Nizar N. Zein, MD
Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation

Address: Mansour A. Parsi, MD, Department of Gastroenterology and Hepatology, A31, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail parsim@ccf.org

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.